Novo Sues Rival Lilly Over Weight-Loss Ads

Summary

Novo Nordisk's group general counsel John Kuckelman discusses a lawsuit against Eli Lilly over what Novo claims are deceptive advertisements comparing weight-loss drugs Wegovy and Zepbound. Kuckelman argues that Lilly uses outdated data, comparing its highest dose to a lower dose of Wegovy, and that actual comparable data shows similar efficacy. He says Novo is seeking an injunction to pull the ads and corrective advertising, and points to a pattern of similar misleading marketing by Lilly. The interview does not contain explicit investment recommendations.

• Novo Nordisk sues Eli Lilly over alleged misleading ads for obesity drugs Wegovy and Zepbound.
• Novo claims Lilly compares highest Zepbound dose to lower Wegovy dose, showing false superiority.
• Data from parallel trials show comparable weight loss (48 lbs vs 47 lbs) between highest doses.
• Novo seeks court order to stop ads and require corrective advertising.
• Kuckelman alleges a pattern of similar deceptive comparisons by Lilly for other drugs.
• The discussion centers on legal arguments, not on financial or stock investment implications.